Cagrilintide

Amylin analogsUnder FDA review (as CagriSema)

Also known as: CagriSema (with semaglutide)

A long-acting amylin analog, mainly tested together with semaglutide.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Amylin is released with insulin and signals fullness. This analog increases satiety through a different pathway from GLP-1.

Evidence by goal

GoalGradeWhat the grade means
Fat loss & weightBHuman trials (smaller, mixed, or approved outside the US)
Blood sugar & metabolicBHuman trials (smaller, mixed, or approved outside the US)

At a glance

Route
Subcutaneous weekly
Half-life
About 7 days

Reported dosing

Trials titrated to 2.4 mg weekly, alone or combined with 2.4 mg semaglutide.

Timing: Same day each week.

Cycle: Continuous in trials.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • Nausea and GI effects, generally milder than GLP-1 drugs alone

Who should avoid it

  • Pregnancy
  • Unregulated online products

Often combined with

Designed to pair with semaglutide.

Key findings

REDEFINE 1 (2025): about 11.8% weight loss alone and about 20% with semaglutide at 68 weeks.

2026 update

CagriSema was filed with the FDA in Dec 2025, with a decision expected around Q4 2026.

Where it is legal (Oct 2026)

USPending
CanadaNot approved
MexicoNot approved
EUPending

Sources

Open Cagrilintide in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top